RecruitingNot ApplicableNCT06079021

COOLEY- Study: ACute on ChrOnic Liver FailurE Using the CYtosorb Device

Sponsor

University Hospital, Antwerp

Enrollment

20 participants

Start Date

Jun 8, 2024

Study Type

INTERVENTIONAL

Conditions

Sarcopenia Ultrasonography Acute-On-Chronic Liver Failure Anticoagulant Adverse Reaction

Summary

A Prospective, Single-Center trial, in Patients With Acute on Chronic Liver Failure. Study of Standard Medical Care Plus CytoSorb® Compared to Standard Medical Care Alone in a historical group.

Eligibility

Min Age: 18 Years

Inclusion Criteria8

adult patients (≥ 18 years) admitted to the University Hospital of Antwerp (UZA), Belgium.
Written informed consent from patient or if not possible due to encephalopathy (\> grade 2): legal representative
acute-on-chronic liver failure (ACLF) grade ≥ 2:
Acute decompensation event (identifiable trigger)
Hepatic encephalopathy grade ≥ 2
Acute kidney injury (AKI) according to Kidney Disease: Improving Global Outcome (KDIGO) criteria stage 3 (≥ 3-fold increase of serum creatinine OR increase of serum creatinine to ≥ 4 mg/dl OR urine output ≤ 0.3 ml/kg/h for ≥ 24 hours OR anuria for ≥ 12 hours)
Serum bilirubin ≥ 10 mg/dl
Hemodynamic instability with vasopressor support (norepinephrine \> 0.05 mcg/kg/min)

Exclusion Criteria4

• known patient will against participation in the study or against the measures applied in the study
a decision made prior to inclusion to stop further treatment of the patient within the next 24 hours
no complete remission of malignancy including hepatocellular carcinoma within the past 12 months
ongoing intermittent or CRRT before study inclusion

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.